Efficacy of different drugs for patients with methamphetamine-induced psychotic disorders: a network meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

LI Fang ¹ , YIN Lei ¹ , YANG Haidong ² ,  CHEN Lizhang ¹

1. Department of Epidemiology and Health Statistics, School of Xiangya Public Health, Central South University, Changsha, 410078, P.R.China;
2. Department of Laboratory, People’s Hospital of Wuqing District, Tianjin, 301700, P.R.China;

Corresponding author：

CHEN Lizhang, Email: liche4005@126.com

Keywords：

Methamphetamine; Psychotic disorders; Quetiapine; Randomized controlled trial; Network meta-analysis

DOI：

10.7507/1672-2531.201702036

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectiveTo systematically review the efficacy of different drugs for patients with methamphetamine-induced psychotic disorders by network meta-analysis.MethodsAn electronical search was conducted in PubMed, The Cochrane Library, Web of Science, EMbase, CNKI, CBM, WanFang Data and VIP databases from inception to October 2016 to collect randomized controlled trials (RCTs) about different drugs for methamphetamine-induced psychotic disorders. Two reviewers independently screened literature, extracted data and assessed the risk bias of included studies, and then RevMan 5.3, R 3.3.2 and JAGS 4.2.0 softwares were used to perform network meta-analysis.ResultsA total of 16 RCTs involving 1 676 patients and 9 kinds of drugs were included. The results of network meta-analysis showed that: compared with the placebo group, olanzapine (OR=28.00, 95%CI 8.10 to 110.00), risperidone (OR=20.00, 95%CI 7.70 to 58.00), quetiapine (OR=30.00, 95%CI 6.60 to 160.00), ziprasidone (OR=28.00, 95%CI 3.70 to 230.00), chlorpromazine (OR=29.00, 95%CI 5.00 to 200.00), aripiprazole (OR=13.00, 95%CI 1.70 to 93.00), haloperidol (OR=19.00, 95%CI 2.10 to 190.00) could significantly improve the psychotic disorders of patients with methamphetamine, respectively, in which quetiapine was the best choice. There were no significant differences between any other pairwise comparisons of these different drugs.ConclusionFor the treatment of psychotic disorders caused by methamphetamine, quetiapine should be of a priority choice, follows by ziprasidone, chlorpromazine, olanzapine, risperidone, aripiprazole or haloperidol in a descending priority. Due to limited quality and quantity of the included studies, more high-quality studies are needed to verify above conclusion.

Citation： LI Fang, YIN Lei, YANG Haidong, CHEN Lizhang. Efficacy of different drugs for patients with methamphetamine-induced psychotic disorders: a network meta-analysis. Chinese Journal of Evidence-Based Medicine, 2017, 17(7): 835-842. doi: 10.7507/1672-2531.201702036 Copy

1.	崔丽. 80 例甲基苯丙胺所致精神障碍临床研究. 中外医疗, 2015(8): 118-119.
2.	Patterns and trends of amphetamine-type stimulants and other drugs: challenges for Asia and the Pacific. UNODC, 2013. Available at: http://idpc.net/publications/2013/11/patterns-and-trends-of-amphetamine-type-stimulants-ats-and-other-drugs-challenges-for-asia-and-the-pacific-2013.
3.	Trends and patterns of amphetamine-type stimulants and new psychoactive substances. UNODC, 2015. Available at: https://www.unodc.org/documents/scientific/2013_Regional_ATS_Report_web.pdf.
4.	周永彬. 甲基苯丙胺所致精神障碍治疗中奥氮平的应用效果观察. 现代诊断与治疗, 2015, 26(23): 5335-5336.
5.	Carvalho M, Carmo H, Costa VM, et al. Toxicity of amphetamines: an update. Arch Toxicol, 2012, 86(8): 1167-1231.
6.	王锋锐, 叶百维, 王文军. 滥用甲基苯丙胺与负性生活事件的相关性分析. 四川精神卫生, 2013, 26(2): 124-125.
7.	Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for healthcare decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health, 2011, 14(4): 423.
8.	曾宪涛, 张超. R 与 Meta 分析. 第一版. 北京: 军事医学科学出版社, 2015: 5.
9.	van Valkenhoef G, Lu GB, De Brock B, et al. Automating network meta-analysis. Res Synth Methods, 2012, 3(4): 285-299.
10.	Tunaru R. Hierarchical Bayesian models for multiple count data. Aust J Stat, 2002, 3(31): 221-229.
11.	易跃雄, 张蔚, 刘小媛, 等. 网状 Meta 分析图形结果解读. 中国循证医学杂志, 2015, 15(1): 103-109.
12.	潘建设. 奥氮平与利培酮治疗冰毒所致精神障碍的临床对照研究. 实用药物与临床, 2014, 17(3): 289-291.
13.	寸永海. 奥氮平治疗冰毒所致精神障碍的临床研究. 中国卫生产业, 2014, (28): 122-123.
14.	金莲玉, 刘忠政. 应用奥氮平与利培酮治疗冰毒所致精神障碍患者的对比分析. 中国民康医学, 2016, 28(3): 57-58.
15.	祝昂明. 喹硫平治疗甲基苯丙胺所致精神障碍的临床观察. 临床医药文献电子杂志, 2015, 2(3): 418-419.
16.	赵庆莲, 侯峰, 张艳霞, 等. 喹硫平治疗甲基苯丙胺所致精神障碍的临床观察. 中国药物依赖性杂志, 2007, 16(6): 435-437.
17.	姚刚. 齐拉西酮治疗甲基苯丙胺所致精神障碍临床疗效观察. 实用医院临床杂志, 2011, 8(6): 126-128.
18.	周芳珍, 陆金进, 程琳. 氯丙嗪治疗甲基苯丙胺所致精神障碍的疗效观察. 河北联合大学学报(医学版), 2013, 15(3): 317-318.
19.	潘建设, 刘林晶. 奥氮平与阿立哌唑治疗冰毒所致精神障碍的临床对照. 中国浙江金华: 浙江省医学会精神病学分会学术年会暨浙江省医师协会精神科医师分会第六届年会, 2013.
20.	赵庆莲, 杨秋兰, 侯峰, 等. 利培酮治疗冰毒所致精神障碍 40 例疗效观察. 中国药物滥用防治杂志, 2007, 13(6): 335-338.
21.	颜昌云, 余升晋, 魏筱龙. 利培酮治疗冰毒所致精神障碍 50 例疗效观察. 中国药物滥用防治杂志, 2010, 16(5): 281-282.
22.	Ling W, Chang L, Hillhouse M, et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction, 2014, 109(9): 1489-1500.
23.	Miles SW, Sheridan J, Russell B, et al. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction, 2013, 108(7): 1279-1286.
24.	Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychophacol, 2008, 33(5): 1162-1170.
25.	Anderson AL, Li SH, Markova D, et al. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend, 2015, 150: 170-174.
26.	Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend, 2008, 96(3): 222-232.
27.	Verachai V, Rukngan W, Chawanakrasaesin K, et al. Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine. Psychopharmacology, 2014, 231(16): 3099-3108.
28.	Lappin JM, Sara GE, Farrell M. Methamphetamine-related psychosis: an opportunity for assertive intervention and prevention. Addiction, 2017, 112(6): 927-928.
29.	Callaghan RC, Cunningham JK, Allebeck P, et al. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry, 2012, 169(4): 389-396.
30.	Rawson RA. Current research on the epidemiology, medical and psychiatric effects, and treatment of methamphetamine use. J Food Drug Anal, 2013, 21(4): S77-S81.
31.	Ohlssen D, Price KL, Xia HA, et al. Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis. Pharm Stat, 2014, 13(1): 55-70.
32.	Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract, 2012, 24(6): 541-550.
33.	白录东, 李万顺, 崔开艳, 等. 喹硫平基因组学研究进展. 精神医学杂志, 2016, 29(3): 206-209.
34.	徐世超, 苏闪芳, 陈智超. 齐拉西酮与利培酮治疗首发精神分裂症的疗效和安全性. 当代医学, 2013, 19(22): 137-138.

1. 崔丽. 80 例甲基苯丙胺所致精神障碍临床研究. 中外医疗, 2015(8): 118-119.
2. Patterns and trends of amphetamine-type stimulants and other drugs: challenges for Asia and the Pacific. UNODC, 2013. Available at: http://idpc.net/publications/2013/11/patterns-and-trends-of-amphetamine-type-stimulants-ats-and-other-drugs-challenges-for-asia-and-the-pacific-2013.
3. Trends and patterns of amphetamine-type stimulants and new psychoactive substances. UNODC, 2015. Available at: https://www.unodc.org/documents/scientific/2013_Regional_ATS_Report_web.pdf.
4. 周永彬. 甲基苯丙胺所致精神障碍治疗中奥氮平的应用效果观察. 现代诊断与治疗, 2015, 26(23): 5335-5336.
5. Carvalho M, Carmo H, Costa VM, et al. Toxicity of amphetamines: an update. Arch Toxicol, 2012, 86(8): 1167-1231.
6. 王锋锐, 叶百维, 王文军. 滥用甲基苯丙胺与负性生活事件的相关性分析. 四川精神卫生, 2013, 26(2): 124-125.
7. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for healthcare decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health, 2011, 14(4): 423.
8. 曾宪涛, 张超. R 与 Meta 分析. 第一版. 北京: 军事医学科学出版社, 2015: 5.
9. van Valkenhoef G, Lu GB, De Brock B, et al. Automating network meta-analysis. Res Synth Methods, 2012, 3(4): 285-299.
10. Tunaru R. Hierarchical Bayesian models for multiple count data. Aust J Stat, 2002, 3(31): 221-229.
11. 易跃雄, 张蔚, 刘小媛, 等. 网状 Meta 分析图形结果解读. 中国循证医学杂志, 2015, 15(1): 103-109.
12. 潘建设. 奥氮平与利培酮治疗冰毒所致精神障碍的临床对照研究. 实用药物与临床, 2014, 17(3): 289-291.
13. 寸永海. 奥氮平治疗冰毒所致精神障碍的临床研究. 中国卫生产业, 2014, (28): 122-123.
14. 金莲玉, 刘忠政. 应用奥氮平与利培酮治疗冰毒所致精神障碍患者的对比分析. 中国民康医学, 2016, 28(3): 57-58.
15. 祝昂明. 喹硫平治疗甲基苯丙胺所致精神障碍的临床观察. 临床医药文献电子杂志, 2015, 2(3): 418-419.
16. 赵庆莲, 侯峰, 张艳霞, 等. 喹硫平治疗甲基苯丙胺所致精神障碍的临床观察. 中国药物依赖性杂志, 2007, 16(6): 435-437.
17. 姚刚. 齐拉西酮治疗甲基苯丙胺所致精神障碍临床疗效观察. 实用医院临床杂志, 2011, 8(6): 126-128.
18. 周芳珍, 陆金进, 程琳. 氯丙嗪治疗甲基苯丙胺所致精神障碍的疗效观察. 河北联合大学学报(医学版), 2013, 15(3): 317-318.
19. 潘建设, 刘林晶. 奥氮平与阿立哌唑治疗冰毒所致精神障碍的临床对照. 中国浙江金华: 浙江省医学会精神病学分会学术年会暨浙江省医师协会精神科医师分会第六届年会, 2013.
20. 赵庆莲, 杨秋兰, 侯峰, 等. 利培酮治疗冰毒所致精神障碍 40 例疗效观察. 中国药物滥用防治杂志, 2007, 13(6): 335-338.
21. 颜昌云, 余升晋, 魏筱龙. 利培酮治疗冰毒所致精神障碍 50 例疗效观察. 中国药物滥用防治杂志, 2010, 16(5): 281-282.
22. Ling W, Chang L, Hillhouse M, et al. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction, 2014, 109(9): 1489-1500.
23. Miles SW, Sheridan J, Russell B, et al. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction, 2013, 108(7): 1279-1286.
24. Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychophacol, 2008, 33(5): 1162-1170.
25. Anderson AL, Li SH, Markova D, et al. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend, 2015, 150: 170-174.
26. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend, 2008, 96(3): 222-232.
27. Verachai V, Rukngan W, Chawanakrasaesin K, et al. Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine. Psychopharmacology, 2014, 231(16): 3099-3108.
28. Lappin JM, Sara GE, Farrell M. Methamphetamine-related psychosis: an opportunity for assertive intervention and prevention. Addiction, 2017, 112(6): 927-928.
29. Callaghan RC, Cunningham JK, Allebeck P, et al. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry, 2012, 169(4): 389-396.
30. Rawson RA. Current research on the epidemiology, medical and psychiatric effects, and treatment of methamphetamine use. J Food Drug Anal, 2013, 21(4): S77-S81.
31. Ohlssen D, Price KL, Xia HA, et al. Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis. Pharm Stat, 2014, 13(1): 55-70.
32. Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract, 2012, 24(6): 541-550.
33. 白录东, 李万顺, 崔开艳, 等. 喹硫平基因组学研究进展. 精神医学杂志, 2016, 29(3): 206-209.
34. 徐世超, 苏闪芳, 陈智超. 齐拉西酮与利培酮治疗首发精神分裂症的疗效和安全性. 当代医学, 2013, 19(22): 137-138.

Chinese Journal of Evidence-Based Medicine

Efficacy of different drugs for patients with methamphetamine-induced psychotic disorders: a network meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content